00:01Novo Nordisk is planning legal and regulatory action against telehealth provider HIMS & HERS
00:06after the company announced it would sell a compounded, lower-cost version of its newly
00:11FDA-approved WegoV weight loss pill, which Novo says is a legal mass compounding of its
00:17drug and risks patient safety.
00:20The Danish drugmaker insists it holds exclusive rights to the approved WegoV formulation and
00:25is seeking to protect its intellectual property and the credibility of U.S. drug approval
00:30standards. HIMS & HERS' version, priced much lower than Novo's branded pill, has already
00:36pressured Novo's stock and reignited tensions after a previous partnership between the companies
00:41dissolved amid similar disputes.
Comments